NuVision, a Nottingham, UK-based company with a product that speeds up healing of eye conditions, raised £1.1M in further funding.
The round, which brings the total raised by the company to over £5M, was led by MEIF Proof of Concept & Early Stage Fund with participation from Midlands Engine Investment Fund, Mercia’s EIS funds, Pioneer Group (formerly the BioCity Group), the University of Nottingham
The company intends to use the funds to accelerate the development of its first two products in advance of a Series A investment in the next 12 months.
Founded in 2015 by Dr Andy Hopkinson based on his research at the University of Nottingham, and led by CEO Andy Hill, NuVision is advancing wound dressings made from the amniotic membrane, the sac that surrounds babies in the womb, and are used to help the surface of the eye regenerate and heal. Its first product, Omnigen, a dry, room-temperature stable product that rehydrates on contact with natural moisture from the eye, is already approved for treatment on the NHS and is used in hospitals and private clinics in the UK and overseas. Omnigen may be applied in the operating theatre or, when used in combination with the company’s bespoke bandage contact lens, OmniLenz, in the outpatient department or clinic. This enables patients to benefit from amniotic membrane without having to undergo surgery and can enable treatment at an earlier stage in the development of their condition.
FinSMEs
09/03/2023